Compare Chevron Corp (CVX) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chevron Corp vs Novartis AG — how do they compare? Chevron Corp trades at $196.14 (market cap $382.34B), while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Chevron Corp is the larger of the two by market cap, and Chevron Corp pays the higher dividend (3.65%). Which is the better fit depends on your goals.
| CVX | NVS | |
|---|---|---|
Market Cap | $382.34B | $298.18B |
Volume | 9,807,834 | — |
Sector | Energy | Health |
52-Week High | $211.14 | $168.62 |
52-Week Low | $146.72 | $119.31 |
Enterprise Value | $410.88B | $339.50B |
Dividend Yield | 3.65% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chevron (CVX) trades at $196.66, up 5.41% today, reflecting strong momentum amid high oil prices. The stock shows bullish technical signals, with recent earnings beats and a consensus analyst price target of $214.25. Revenue declined to $184.43B in 2025, but net income margin held at 9.87%, with robust cash flow from operations of $33.94B. Recent news highlights strategic investments in Argentina and Greece, leveraging geopolitical tensions to boost production prospects.
Outlook is positive with oil price tailwinds and operational efficiency, but risks include volatile energy markets and debt increases. The stock offers a solid dividend yield and growth potential, supported by analyst bullishness, though investors should monitor execution on new projects and macroeconomic shifts affecting energy demand.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
